A ruthenium anticancer compound interacts with histones and impacts differently on epigenetic and death pathways compared to cisplatin

Ruthenium complexes are considered as potential replacements for platinum compounds in oncotherapy. Their clinical development is handicapped by a lack of consensus on their mode of action. In this study, we identify three histones (H3.1, H2A, H2B) as possible targets for an anticancer redox organor...

Descripción completa

Detalles Bibliográficos
Autores principales: Licona, Cynthia, Spaety, Marie-Elodie, Capuozzo, Antonelle, Ali, Moussa, Santamaria, Rita, Armant, Olivier, Delalande, Francois, Dorsselaer, Alain Van, Cianferani, Sarah, Spencer, John, Pfeffer, Michel, Mellitzer, Georg, Gaiddon, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356824/
https://www.ncbi.nlm.nih.gov/pubmed/27935863
http://dx.doi.org/10.18632/oncotarget.13711

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356824/
https://www.ncbi.nlm.nih.gov/pubmed/27935863
http://dx.doi.org/10.18632/oncotarget.13711

Ejemplares similares